Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
The Third People's Hospital of Zigong, Zigong, Sichuan, China.
Eur J Med Res. 2022 Feb 22;27(1):26. doi: 10.1186/s40001-022-00647-6.
To determine the effect of polymorphisms and mutations in angiotensin-converting enzyme 2 (ACE2) and Type 2 transmembrane serine proteases (TMPRSS2) genes on susceptibility to corona virus disease 2019 (COVID-19) and patient prognosis.
From December 2019 to the current time, an outbreak of epidemic of COVID-19, characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred around the world. It is now clear that SARS-CoV-2 binds to human ACE2 receptors, with expression of these receptors correlated with the rate of SARS-CoV-2 infection and mortality. Polymorphisms in individual patient factors, such as ACE2 and TMPRSS2 genes have been linked with an increase in negative outcomes, although evidence to affirm remains debatable.
Here, we performed a systematic review, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, with the aim of assessing whether polymorphisms in ACE2 and TMPRSS2 genes affect the COVID-19 condition. We extensively searched PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science databases, for relevant articles and reports published in English between December 2019 and December 2021.
A total of 495 full-text articles were downloaded, of which 185 were excluded after preliminary examination as they were duplicates. Finally, 310 articles were evaluated, by reading their titles and abstracts, and 208 of them eliminated based on our selection criteria. Finally, 33 articles met our inclusion criteria and were included in the final assessment. Genetic data from 33,923 patients with COVID-19 drawn from the general population and deriving from over 160 regions and 50 countries, as well as approximately 560,000 samples from global-public genetic databases, were included in our analysis. Ultimately, we identified 10 SNPs and 21 mutations in the ACE2 gene, along with 13 SNPs and 12 variants in the TMPRSS2 gene, which may be associated with COVID-19.
ACE2 and TMPRSS2 play vital roles in the onset, development, and prognosis of SARS-CoV-2 infection, and have both been strongly associated with vulnerability, intensity, and the clinical result of COVID-19. Overall, these genetic factors may have potential for future development of personalized drugs and vaccines against COVID-19.
CRD42021239400 in PROSPERO 2021.
确定血管紧张素转换酶 2（ACE2）和 2 型跨膜丝氨酸蛋白酶（TMPRSS2）基因的多态性和突变对 2019 年冠状病毒病（COVID-19）易感性和患者预后的影响。
自 2019 年 12 月以来，以严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）为特征的 COVID-19 爆发在全球范围内发生。现在已经清楚，SARS-CoV-2 与人类 ACE2 受体结合，这些受体的表达与 SARS-CoV-2 感染和死亡率相关。个体患者因素（如 ACE2 和 TMPRSS2 基因）的多态性与不良结局的增加有关，尽管仍有争议。
在这里，我们根据系统评价和荟萃分析（PRISMA）指南的标准进行了系统评价，目的是评估 ACE2 和 TMPRSS2 基因中的多态性是否影响 COVID-19 状况。我们广泛搜索了 PubMed、MEDLINE、Embase、Cochrane 图书馆和 Web of Science 数据库，以获取 2019 年 12 月至 2021 年 12 月期间以英文发表的相关文章和报告。
共下载了 495 篇全文文章，其中 185 篇在初步检查后因重复而被排除。最终，通过阅读标题和摘要评估了 310 篇文章，根据我们的选择标准淘汰了 208 篇。最终，符合纳入标准的 33 篇文章被纳入最终评估。我们的分析包括来自全球 160 多个地区和 50 个国家的普通人群中 33923 例 COVID-19 患者的遗传数据，以及来自全球公共遗传数据库的大约 560000 个样本。最终，我们确定了 ACE2 基因中的 10 个单核苷酸多态性（SNP）和 21 个突变，以及 TMPRSS2 基因中的 13 个 SNP 和 12 个变体，这些可能与 COVID-19 有关。
ACE2 和 TMPRSS2 在 SARS-CoV-2 感染的发病、发展和预后中发挥着重要作用，并且都与 COVID-19 的脆弱性、强度和临床结果密切相关。总体而言，这些遗传因素可能具有针对 COVID-19 开发个性化药物和疫苗的潜力。
PROSPERO 2021 中的 CRD42021239400。
